EFFICACY OF CARBOPLATIN plus WEEKLY NAB-PACLITAXEL FOR ELDERLY ADVANCED/RECURRENT NON-SMALL CELL LUNG CANCER (E-NSCLC)

被引：0
|
作者：
Shibata, Kazuhiko [1 ,2 ]
Shibata, Yoshihiro [1 ]
Takase, Misae [2 ]
Takahashi, Miyuki [2 ,3 ]
机构：
[1] Koseiren Takaoka Hosp, Dept Med Oncol, Toyama, Japan
[2] Koseiren Takaoka Hosp, Comprehens Canc Ctr, Toyama, Japan
[3] Koseiren Takaoka Hosp, Dept Nursing, Toyama, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu436.35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-4
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of weekly nab-paclitaxel plus carboplatin advanced non-small cell lung cancer
    Satouchi, Miyako
    Okamoto, Isamu
    Sakai, Hiroshi
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Ohmatsu, Hironobu
    Nogami, Naoyuki
    Takeda, Koji
    Mitsudomi, Tetsuya
    Kasahara, Kazuo
    Negoro, Shunichi
    LUNG CANCER, 2013, 81 (01) : 97 - 101
  • [2] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer NSCLC: Dose Modification Analysis
    Postmus, Pieter E.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Li, Li
    Ong, Teng Jin
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S658 - S658
  • [3] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology
    Gridelle, Cesare
    Chen, Tianlei
    Ko, Amy
    Ong, Teng Jin
    O'Brien, Mary
    Socinski, Mark
    Postmus, Pieter
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S213 - S213
  • [4] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Sakai, Mizu
    Anabuki, Kazuki
    Takamatsu, Kazufumi
    Mukaida, Kenichi
    Kobayashi, Kana
    Yamagami, Takuji
    Yokoyama, Akihito
    IN VIVO, 2024, 38 (01): : 259 - 263
  • [6] nab-Paclitaxel plus carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology
    Gridelli, C.
    Ko, A.
    O'Brien, M.
    Ong, T. J.
    Socinskis, M. A.
    Postmus, P. E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S154 - S155
  • [7] Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results
    Gentzler, R. D.
    Mohindra, N. A.
    Hanna, N.
    Chae, Y. K.
    Jalal, S. I.
    Hall, R.
    Villaflor, V. M.
    Reckamp, K. L.
    Koczywas, M.
    Sullivan, D.
    Wood, L.
    Patel, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 236 - 236
  • [8] ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Langer, Corey J.
    Anderson, Eric C.
    Jotte, Robert M.
    Goldman, Jonathan Wade
    Haggstrom, Daniel Ernest
    Socoteanu, Matei Paul
    Smith, David A.
    Dakhil, Christopher
    Konduri, Kartik
    Kim, Edward S.
    Ong, Teng Jin
    Sanford, Alexandra
    Amiri, Katayoun
    Weiss, Jared
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Hawkins, M. J.
    Manikhas, G.
    Makhson, A.
    Cheporov, S.
    Orlov, S.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer
    Shota Omori
    Hideyuki Harada
    Keita Mori
    Yasushi Hisamatsu
    Yuko Tsuboguchi
    Hiroshige Yoshioka
    Ryotaro Morinaga
    Haruko Daga
    Takayasu Kurata
    Toshiaki Takahashi
    Investigational New Drugs, 2022, 40 : 106 - 114
12345